In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a pediatric use marketing authorization for the medicinal product Aqumeldi, intended for the treatment of heart failure in children from birth to less than 18 years of age. The applicant for this medicinal product is Proveca Pharma Limited. Aqumeldi was approved for medical use in the European Union in November 2023.